News &amp; Updates

Combination treatment with mecobalamin tablets plus vitamin E soft capsules works in patients with recurrent oral ulcer, alleviating pain and improving the quality of life, according to a study.

Mecobalamin plus vitamin E a good combo against recurrent mouth ulcer

Aumolertinib a win in EGFR T790M-positive advanced NSCLC

The novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib appears to be effective in the treatment of patients with EGFR T790M-positive advanced nonsmall cell lung carcinoma (NSCLC) following progression on first- and second-generation EGFR TKI therapy, according to data from the phase II APOLLO Registrational Trial.

Aumolertinib a win in EGFR T790M-positive advanced NSCLC

23 Dec 2021

Time to prophylaxis linked to VTE incidence in traumatic brain injury patients

Most patients with traumatic brain injury receive delayed prophylaxis, with no association seen between incidence of venous thromboembolism (VTE) and prophylaxis regimen, suggests a study. However, a significant difference is observed in VTE incidence stratified by time to prophylaxis.

Time to prophylaxis linked to VTE incidence in traumatic brain injury patients

23 Dec 2021

Zolpidem, zopiclone help insomniac seniors with Alzheimer’s disease sleep

Short-term treatment with zolpidem or zopiclone in older patients with Alzheimer’s disease and insomnia appears beneficial, even though safety and tolerance issues have yet to be personalized in healthcare settings and further investigated in subsequent trials, according to a study.

Zolpidem, zopiclone help insomniac seniors with Alzheimer’s disease sleep

22 Dec 2021

Short-course vancomycin plus piperacillin-tazobactam tied to fewer AKI incidence

Noncritically ill patients treated with a short course of vancomycin plus piperacillin-tazobactam (VPT) are less likely to experience acute kidney injury (AKI) than those who received an extended course, reports a study.

Short-course vancomycin plus piperacillin-tazobactam tied to fewer AKI incidence

Mitapivat inches its way towards becoming first approved therapy for PK deficiency

22 Dec 2021 by

The investigational pyruvate kinase R (PKR) activator mitapivat continued to show benefit for individuals with PK deficiency (PKD) regardless of transfusion status, according to updated findings from the phase III ACTIVATE trials and the long-term extension (LTE) study.

Mitapivat inches its way towards becoming first approved therapy for PK deficiency

True North: Ozanimod benefits in ulcerative colitis evident in various populations

21 Dec 2021 by

A post hoc analysis of the phase III True North study showed that the benefits of ozanimod on clinical remission and response in patients with moderate-to-severe ulcerative colitis (UC) as seen in the global analysis were consistent in the analysis of the North American cohort.

True North: Ozanimod benefits in ulcerative colitis evident in various populations

Sleeve gastrectomy vs gastric bypass for weight loss: Which is safer?

21 Dec 2021 by

Sleeve gastrectomy was associated with a lower risk of mortality and complications over 5 years compared with gastric bypass, although the former intervention comes with an increased risk of surgical revision, reveals a recent study on patients undergoing bariatric surgery for weight loss.

Sleeve gastrectomy vs gastric bypass for weight loss: Which is safer?

Hypotension prevents boosting of sacubitril/valsartan doses for Asians with ACHD-related HF

21 Dec 2021 by

The angiotensin receptor-neprilysin inhibitors (ARNI) sacubitril/valsartan does not appear to help manage heart failure (HF) in Asian patients with adult congenital heart disease (ACHD), with a small study from Singapore showing that the drug can only be tolerated at suboptimal doses and that hypotension prevents uptitration.

Hypotension prevents boosting of sacubitril/valsartan doses for Asians with ACHD-related HF

Is continuous infusion labetalol haemodynamically safe for type B aortic dissections?

Treatment with high-dose continuous intravenous labetalol (HD-CIVL) results in a nonstatistically significant higher incidence of haemodynamic instability compared to an esmolol combination (EC) regimen in patients with type B aortic dissections (TBADs), results of a study have shown.

Is continuous infusion labetalol haemodynamically safe for type B aortic dissections?